Rethinking the bile acid/gut microbiome axis in cancer

CORA will be unavailable from 08:00- 09:00 for regular maintenance on Tuesday, 28th May 2019. Apologies for any inconvenience this may cause.

Show simple item record

dc.contributor.author Phelan, John P.
dc.contributor.author Reen, F. Jerry
dc.contributor.author Caparros-Martin, Jose A.
dc.contributor.author O'Connor, Rosemary
dc.contributor.author O'Gara, Fergal
dc.date.accessioned 2018-02-20T13:24:12Z
dc.date.available 2018-02-20T13:24:12Z
dc.date.issued 2017
dc.identifier.citation Phelan, J. P., Reen, F. J., Caparros-Martin, J. A., O'Connor, R. and O'Gara, F. (2017) 'Rethinking the bile acid/gut microbiome axis in cancer', Oncotarget, 8(70), pp.115736-115747. doi:10.18632/oncotarget.22803 en
dc.identifier.volume 8
dc.identifier.issued 70
dc.identifier.startpage 115736
dc.identifier.endpage 115747
dc.identifier.issn 1949-2553
dc.identifier.uri http://hdl.handle.net/10468/5503
dc.identifier.doi 10.18632/oncotarget.22803
dc.description.abstract Dietary factors, probiotic agents, aging and antibiotics/medicines impact on gut microbiome composition leading to disturbances in localised microbial populations. The impact can be profound and underlies a plethora of human disorders, including the focus of this review; cancer. Compromised microbiome populations can alter bile acid signalling and produce distinct pathophysiological bile acid profiles. These in turn have been associated with cancer development and progression. Exposure to high levels of bile acids, combined with localised molecular/genome instability leads to the acquisition of bile mediated neoplastic alterations, generating apoptotic resistant proliferation phenotypes. However, in recent years, several studies have emerged advocating the therapeutic benefits of bile acid signalling in suppressing molecular and phenotypic hallmarks of cancer progression. These studies suggest that in some instances, bile acids may reduce cancer phenotypic effects, thereby limiting metastatic potential. In this review, we contextualise the current state of the art to propose that the bile acid/gut microbiome axis can influence cancer progression to the extent that classical in vitro cancer hallmarks of malignancy (cell invasion, cell migration, clonogenicity, and cell adhesion) are significantly reduced. We readily acknowledge the existence of a bile acid/gut microbiome axis in cancer initiation, however, in light of recent advances, we focus exclusively on the role of bile acids as potentially beneficial molecules in suppressing cancer progression. Finally, we theorise that suppressing aggressive malignant phenotypes through bile acid/gut microbiome axis modulation could uncover new and innovative disease management strategies for managing cancers in vulnerable cohorts en
dc.description.sponsorship Department of Agriculture, Food and the Marine (FIRM/RSF/CoFoRD; FIRM 08/RDC/629; FIRM 1/F009/MabS; FIRM 13/F/516); Irish Research Council for Science, Engineering and Technology (PD/2011/2414; GOIPG/2014/647); Health Research Board/Irish Thoracic Society (MRCG-2014-6); Marine Institute (Beaufort award C2CRA 2007/082); Teagasc (Walsh Fellowship 2013) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Impact Journals LLC en
dc.relation.uri http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=22803&path[]=71990
dc.rights © 2017, Phelan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. en
dc.rights.uri https://creativecommons.org/licenses/by/3.0/
dc.subject Bile acids en
dc.subject Microbiome en
dc.subject Gut-axis en
dc.subject Cancer en
dc.subject Dysbiosis en
dc.title Rethinking the bile acid/gut microbiome axis in cancer en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Fergal O'Gara, Microbiology, University College Cork, Cork, Ireland. +353-21-490-3000 Email: f.ogara@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Teagasc
dc.contributor.funder Marine Institute
dc.contributor.funder Irish Thoracic Society
dc.contributor.funder Health Research Board
dc.contributor.funder Irish Research Council for Science, Engineering and Technology
dc.contributor.funder Department of Agriculture, Food and the Marine
dc.contributor.funder Science Foundation Ireland
dc.contributor.funder European Commission
dc.description.status Peer reviewed en
dc.identifier.journaltitle Oncotarget en
dc.internal.IRISemailaddress f.ogara@ucc.ie en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Technology and Innovation Development Award (TIDA)/14/TIDA/2438/IE/Next Generation Antibiotics: anti-biofilm, anti-pathogenic natural bioactives from marine microorganisms./
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Technology and Innovation Development Award (TIDA)/12/TIDA/B2405/IE/Optimised detection of key biomarkers of Pseudomonas aeruginosa towards a clinical application/
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Technology and Innovation Development Award (TIDA)/12/TIDA/B2411/IE/Development of small molecule therapeutics for medical intervention: anti-biofilm inhibitors for the medical device sector./
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Technology and Innovation Development Award (TIDA)/13/TIDA/B2625/IE/Small molecule inhibitors of HIF-1: a new class of anti-cancer therapeutics./
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/
dc.relation.project info:eu-repo/grantAgreement/EC/H2020::IA/634486/EU/Industrial Applications of Marine Enzymes: Innovative screening and expression platforms to discover and use the functional protein diversity from the sea/INMARE
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP3::PEOPLE/256596/EU/Dissecting the role of a novel transcriptional regulator in microbial-host interactomes./MEXT REGULATION
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::KBBE/287589/EU/Marine Microbial Biodiversity, Bioinformatics and Biotechnology/MICRO B3
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::KBBE/311975/EU/Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications/MACUMBA
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::KBBE/312184/EU/Increasing Value and Flow in the Marine Biodiscovery Pipeline/PHARMASEA
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP3::PEOPLE/607786/EU/BluePharmTrain/BLUEPHARMTRAIN


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2017, Phelan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Except where otherwise noted, this item's license is described as © 2017, Phelan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement